Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01915303 : Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
PhasePhase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion criteria:

1. Written informed consent obtaine prior to screening procedures

2. Adult patients with confirmed diagnosis of ACTH-dependent Cushing's disease as
evidenced by all of the following:

1. The mean of three 24-hour urine samples collected within 2 weeks > 1xULN with 2
out of 3 samples >ULN

2. Morning plasma ACTH within the normal or above normal range

3. Either MRI confirmation of pituitary adenoma > 6 mm, or inferior petrosal sinus
gradient >3 after CRH stimulation for those patients with a tumor less than or
equal to 6 mm*. For patients who have had prior pituitary surgery,
histopathology confirming an ACTH staining adenoma *If IPSS had previously been
performed without CRH (e.g. with DDAVP), then a central to peripheral
pre-stimulation gradient > 2 is required. If IPSS had not previously been
performed, IPSS with CRH stimulation is required.

3. Patients with de novo Cushing's disease can be included only if they are not
considered candidates for pituitary surgery (e.g. poor surgical candidates,
surgically unapproachable tumors, patients who refuse to have surgical treatment)

4. Male or female patients aged 18 years or greater

5. Karnofsky performance status ? 60 (i.e. requires occasional assistance, but is able
to care for most of their personal needs)

6. Patients on medical treatment for Cushing's disease the following washout periods
must be completed before screening assessments are performed

- Inhibitors of steroidogenesis (ketoconazole, metyrapone): 1 week

- Pituitary directed agents: Dopamine agonists (bromocriptine, cabergoline) and
PPAR? agonists (rosiglitazone or pioglitazone): 4 weeks

- Octreotide LAR, Lanreotide SR and Lanreotide autogel: 14 weeks

- Octreotide (immediate release formulation): 1 week

- Progesterone receptor antagonist (mifepristone): 4 weeks

7. Patients can be considered to enter the trial if they meet any one of the following
criteria: 1) They are naive to pasireotide 2) They have received pasireotide in the
past and have been discontinued because of lack of efficacy (2 weeks for washout
prior to screening for patients treated with pasireotide subcutaneously and 12 weeks
of washout prior to screening for patients treated with pasireotide LAR) 3) Patients
who are on maximal tolerated dose but have not achieved biochemical control

8. Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, if they are using highly effective methods of contraception during
dosing and for 30 days after stopping study medication.

9. Male participants in the trial must agree to use a condom during intercourse, and not
to father a child during the study and for the period of 30 days following stopping
of the study treatment.

Exclusion criteria:

1. Patients with compression of the optic chiasm causing any visual field defect that
requires surgical intervention

2. Diabetic patients with poor glycemic control as evidenced by HbA1c >8%

3. Patients with risk factors for torsade de pointes, i.e. patients with a baseline QTcF
>450 ms in males, and > 460 ms in females. hypokalemia, hypomagnesaemia, uncontrolled
hypothyroidism, family history of long QT syndrome, or concomitant medications known
to prolong QT interval.

4. Patients with clinically significant valvular disease.

5. Patients with Cushing's syndrome due to ectopic ACTH secretion

6. Patients with hypercortisolism secondary to adrenal tumors or nodular (primary)
bilateral adrenal hyperplasia

7. Patients who have congestive heart failure (NYHA Class III or IV), unstable angina,
sustained ventricular tachycardia, clinically significant bradycardia, advanced heart
block, history of acute MI less than one year prior to study entry or clinically
significant impairment in cardiovascular function

8. Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic
persistent hepatitis, or patients with ALT/AST > 2 X ULN, serum bilirubin >2.0 X ULN

9. Patients with serum creatinine >2.0 X ULN

10. Patients with WBC <3 X 10e9/L; Hb 90% < LLN; PLT <100 X 10e9/L

11. Patients with presence of Hepatitis B surface antigen (HbsAg)

12. Patients with presence of Hepatitis C antibody test (anti-HCV)

13. Patients with severe hepatic impairment (Child Pugh C) and hypersensitivity to
pasireotide or cabergoline

14. Patients with lung, pericardial, and retroperitoneal fibrosis; gastro-duodenal ulcer
or digestive haemorrhage, galactose intolerance, Parkinson's disease, uncontrolled
hypertension and Raynauds syndrome.

15. Pregnant or nursing (lactating) women where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test (> 5 mIU/ml)

16. Patients with end-stage renal failure and/or hemodialysis

17. Patients with presence of active or suspected acute or chronic uncontrolled infection

18. Patients with a history of non-complance to medical regimens or who are considered
potentially unreliable or whill be unable to complete the entire study

19. Patients with presence of Hepatitis B surface antigen (HbsAg)

20. Patients with presence of Hepatitis C antibody test (anti-HCV)

21. Patients with severe hepatic impairment (Child Pugh C) and hpersensitivity to
pasireotide or cabergoline

22. Patients with lung, pericardial, and retroperitoneal fibrosis; gastroduodenal ulcer
or digestive haemorrhage, galactose intolerance, Parkinson's disease, uncontrolled
hypertension and Raynaud's syndrome

23. Pregnant or nursing (lactating) women where pregnancy is defined as the state of a
female after conception and until the terminiation of gestation, confirmed by a
positive hCG laboratory test (> 5mIU/mL)

24. Patients with end-stage renal failure and/or hemodialysis
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01915303      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740